Treatment of refractory cutaneous dermatomyositis with oral sirolimus

Abstract

We present a single-centre retrospective case series of four patients with clinically amyopathic dermatomyositis from our institution who were treated with oral sirolimus after failing multiple other therapies. Three of our four patients achieved significant control of disease and were able to decrease their prednisone dose while on sirolimus. There were no clinically significant infections or new malignancies during sirolimus treatment in any of the patients.